M&A Strategy Strengthens Boston Scientific's Growth Prospects

Key Takeaways BSX's recent acquisitions enhanced CRM, Endoscopy, Interventional Cardiology, Oncology and EP portfolios.BSX's acquisitions drove 420 bps of Q3 sales growth, lifting organic revenues to 15.3% above guidance.Boston Scientific advanced its Neuromodulation reach with an agreement to acquire all of Nalu Medical.Over the past several years, Boston Scientific (BSX) has pursued a series of acquisitions in support of its growth strategy, both strengthening its core businesses and expanding into high-g ...